23 Results for "

paroxysmal

" in MedChemExpress (MCE) Product Catalog:
Products (23)

23 Results for "paroxysmal" in MCE Product Catalog:

Cat. No.: HY-P3252AS
Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
loading...
    loading...
Cat. No.: HY-181040
CAS No.: 3049710-19-9
Target:  

Complement System

Research Areas:  

Inflammation/Immunology

Factor B-IN-8 (Compound (3R ,4R )-15) is a potent, selective and orally active factor B inhibitor with an IC50 of 10.2 nM. Factor B-IN-8 can effectively inhibit the binding of factor B to C3b and the subsequent formation of C3 convertase (C3bBb). Factor B-IN-8 can inhibit the deposition of membrane attack complex (MAC) mediated by alternativepathway with an IC50 of 59.3 nM. Factor B-IN-8 can reduce the cleavage of factor B protein and decrease the deposition of complement C3d in the glomeruli and renal tubules. Factor B-IN-8 can be used for researches of arthritis and paroxysmal nocturnal hemoglobinuria (PNH) .
loading...
    loading...
Cat. No.: HY-P992456
Target:  

Complement System

SAR-443809 is a monoclonal antibody targeting complement factor Bb that inhibits the alternative complement pathway. SAR-443809 blocks the cleavage of C3 and factor B via selective binding to the activated form factor Bb, with a KD of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for research on hematological and renal disorders mediated by abnormal alternative complement pathway activity .
loading...
    loading...